Cargando…
Immunotherapy of ovarian cancer with a monoclonal antibody specific for the extracellular domain of anti-Müllerian hormone receptor II
Epithelial ovarian carcinoma (EOC) is the most prevalent and lethal form of ovarian cancer. The low five-year overall survival after EOC diagnosis indicates an urgent need for more effective ways to control this disease. Anti-Müllerian hormone receptor 2 (AMHR2) is an ovarian protein overexpressed i...
Autores principales: | Mazumder, Suparna, Swank, Valerie, Komar, Anton A., Johnson, Justin M., Tuohy, Vincent K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7244012/ https://www.ncbi.nlm.nih.gov/pubmed/32499873 http://dx.doi.org/10.18632/oncotarget.27585 |
Ejemplares similares
-
Correction: Immunotherapy of ovarian cancer with a monoclonal antibody specific for the extracellular domain of anti-Müllerian hormone receptor II
por: Mazumder, Suparna, et al.
Publicado: (2022) -
Regulation of Murine Ovarian Epithelial Carcinoma by Vaccination against the Cytoplasmic Domain of Anti-Müllerian Hormone Receptor II
por: Sakalar, Cagri, et al.
Publicado: (2015) -
Formulation of an ovarian cancer vaccine with the squalene-based AddaVax adjuvant inhibits the growth of murine epithelial ovarian carcinomas
por: Mazumder, Suparna, et al.
Publicado: (2022) -
Targeted Vaccination against Human α-Lactalbumin for Immunotherapy and Primary Immunoprevention of Triple Negative Breast Cancer
por: Tuohy, Vincent K., et al.
Publicado: (2016) -
Anti-Müllerian Hormone and Ovarian Reserve: Update on Assessing Ovarian Function
por: Moolhuijsen, Loes M E, et al.
Publicado: (2020)